US FDA approves Insmed's lung disease drug
The U.S. FDA has approved Insmed's oral drug, Brinsupri, for treating non-cystic fibrosis bronchiectasis, marking it as the first treatment for this chronic lung disease. This condition affects 350,000 to 500,000 adults in the U.S. Brinsupri functions by inhibiting inflammatory enzymes in white blood cells, reducing lung damage caused by overactive immune responses.
Aug 12 (Reuters) - The U.S. Food and Drug Administration has approved Insmed’s (INSM.O) oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition.
Insmed’s drug, branded as Brinsupri, targets non-cystic fibrosis bronchiectasis, a chronic lung condition characterized by permanently damaged airways, leading to persistent cough and excessive mucus production.
It affects 350,000 to 500,000 adults in the U.S., according to the American Lung Association.
Brinsupri works by blocking certain inflammatory enzymes in the white blood cells, preventing them from becoming overactive and damaging the lungs.
